Taking people in Spanyolország4. fázis
Insulin resistance in type 2 diabetes: evaluating the pathogenic mechanisms of insulin resistance in the myocardium and the effects of the treatments with GLP-1RA and SGLT2i
Key facts
- Where
- Barcelona, SpanyolországSee the site
- Phase
- 4. fázis
Where in Spanyolország
- Hospital Universitari Vall d'HebronBarcelona, SpanyolországTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
- Trial code
- EU 2025-523374-17-03
- Record updated
- 2026. június 19.
- Original description
To determine by means of 18F-FDG PET/CT and 99mTc-Tetrofosmin SPECT whether myocardial IR affects cardiac function and coronary flow and is therefore a risk factor for cardiovascular events and diabetic cardiomyopathy in DM2 patients with myocardial IR phenotypeRead full original descriptionShow less
To determine by means of 18F-FDG PET/CT and 99mTc-Tetrofosmin SPECT whether myocardial IR affects cardiac function and coronary flow and is therefore a risk factor for cardiovascular events and diabetic cardiomyopathy in DM2 patients with myocardial IR phenotype
Inclusion: BMI around 30 kg/m2; DM2; no-smoking; no-alcohol; HbA1c between 7-9%.
Exclusion: previous CVD events; treatment with SGLT2 inhibitors or GLP-1 analogs; hepatic and kidney complications; claustrophobia to PET/CT and SPECT.